Curis is announcing that it has achieved the previously stated goal of dosing the first five patients in the TakeAim CLL study and reaffirmed its expectation to report initial CLL data in 5-10 patients in December 2026. (Curis Press Release) Jul 30, 2026
Trial status • Chronic Lymphocytic Leukemia
|